Immutep (IMMP) Income from Non-Controlling Interests (2011 - 2017)
Immutep (IMMP) posted Income from Non-Controlling Interests of -$589775.1 for Q1 2017, down 396.08% on a QoQ basis from $199195.6 in Q2 2016, and down 256.81% year-over-year from $376106.8 in Q1 2016.
Immutep (IMMP) Income from Non-Controlling Interests (2011 - 2017) Analysis & Trends
Immutep's Income from Non-Controlling Interests history runs 3 years deep, the most recent figure standing at -$589775.1 for Q1 2017.
- Quarterly Income from Non-Controlling Interests fell 256.81% year-over-year to -$589775.1 in Q1 2017, while the trailing twelve-month figure through Mar 2017 was -$555796.1 (changed N/A YoY) and the FY2016 annual result came in at $229235.4, up 580.98% from the prior year.
- Income from Non-Controlling Interests was -$589775.1 for Q1 2017 at Immutep, down from $199195.6 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $199195.6 in Q2 2016 and bottomed at -$589775.1 in Q1 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Immutep | 562.38 Mn | 562.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2017 | -589,775.11 |
| Jun 30, 2016 | 199,195.56 |
| Mar 31, 2016 | -165,290.84 |
| Jun 30, 2011 | 74.32 |